-
Je něco špatně v tomto záznamu ?
The association between uncarboxylated matrix Gla protein and lipoprotein-associated phospholipase A2
O. Mayer, J. Seidlerová, J. Vaněk, L. Kielbergerová, J. Bruthans, J. Filipovský, P. Wohlfahrt, R. Cífková, L. Trefil, MH. Knapen, NE. Drummen, C. Vermeer,
Jazyk angličtina Země Irsko
Typ dokumentu časopisecké články, práce podpořená grantem
Grantová podpora
NT12102
MZ0
CEP - Centrální evidence projektů
NT13186
MZ0
CEP - Centrální evidence projektů
- MeSH
- 1-alkyl-2-acetylglycerofosfocholinesterasa krev MeSH
- analýza přežití MeSH
- biologické markery krev MeSH
- extracelulární matrix - proteiny krev MeSH
- kardiovaskulární nemoci krev mortalita MeSH
- lidé středního věku MeSH
- lidé MeSH
- proporcionální rizikové modely MeSH
- prospektivní studie MeSH
- proteiny vázající vápník krev MeSH
- rizikové faktory MeSH
- senioři MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Geografické názvy
- Nizozemsko MeSH
BACKGROUND: Lipoprotein-associated phospholipase A2 (Lp-PLA2) is independently associated with cardiovascular risk, probably via inflammatory activity in sclerotic plaque. We speculated whether Lp-PLA2 has a role in the aetiology of vascular calcifications, estimated from circulating uncarboxylated matrix Gla protein (MGP) species and whether we could find a potential interaction of Lp-PLA2 and MGP in terms of mortality. MATERIALS AND METHODS: We examined 798 patients (mean age 65.1 years) with stable vascular disease and followed them in a prospective study. Both, desphospho-uncarboxylated and total MGP (dp-ucMGP or t-ucMGP) were quantified by pre-commercial ELISA assays, developed by VitaK (Maastricht, The Netherland) RESULTS: Lp-PLA2 activity was independently positively associated with desphospho-uncarboxylated MGP (dp-ucMGP) [β coeff = 0.098, p=0.006]. 1SD of Lp-PLA2 activity was associated with 37% increased risk (p=0.001) of elevated dp-ucMGP (≥977 pmol/L, top quartile). In the Cox proportional hazard model adjusted for conventional risk factors, the patients in the highest quartile of dp-ucMGP or lowest quintile of total-uncarboxylated ucMGP (<2660 nmol/L) had higher risk of all-cause mortality [HRR 2.79 (95% CI 1.97-3.94) and HRR 1.69 (95% CI 1.18-2.42), respectively]. We observed no effect of high Lp-PLA2 activity (≥195 nmol/min/mL) on total mortality. CONCLUSIONS: We assume that Lp-PLA2 is involved in vascular calcification and that dp-ucMGP is a more appropriate biomarker of residual risk than Lp-PLA2 itself.
Biomedical Center Medical Faculty of Charles University Pilsen Czech Republic
Department of Clinical Biochemistry and Hematology University Hospital Pilsen Pilsen Czech Republic
Department of Neurology University Hospital Pilsen Czech Republic
International Clinical Research Centre St Anne's University Hospital Brno Brno Czech Republic
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc16021027
- 003
- CZ-PrNML
- 005
- 20170523161321.0
- 007
- ta
- 008
- 160722s2015 ie f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.maturitas.2014.10.003 $2 doi
- 024 7_
- $a 10.1016/j.maturitas.2014.10.003 $2 doi
- 035 __
- $a (PubMed)25458708
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ie
- 100 1_
- $a Mayer, Otto, $u 2nd Department of Internal Medicine, Medical Faculty of Charles University and University Hospital, Pilsen, Czech Republic; Biomedical Center, Medical Faculty of Charles University, Pilsen, Czech Republic. Electronic address: mayero@fnplzen.cz. $d 1969- $7 xx0053346
- 245 14
- $a The association between uncarboxylated matrix Gla protein and lipoprotein-associated phospholipase A2 / $c O. Mayer, J. Seidlerová, J. Vaněk, L. Kielbergerová, J. Bruthans, J. Filipovský, P. Wohlfahrt, R. Cífková, L. Trefil, MH. Knapen, NE. Drummen, C. Vermeer,
- 520 9_
- $a BACKGROUND: Lipoprotein-associated phospholipase A2 (Lp-PLA2) is independently associated with cardiovascular risk, probably via inflammatory activity in sclerotic plaque. We speculated whether Lp-PLA2 has a role in the aetiology of vascular calcifications, estimated from circulating uncarboxylated matrix Gla protein (MGP) species and whether we could find a potential interaction of Lp-PLA2 and MGP in terms of mortality. MATERIALS AND METHODS: We examined 798 patients (mean age 65.1 years) with stable vascular disease and followed them in a prospective study. Both, desphospho-uncarboxylated and total MGP (dp-ucMGP or t-ucMGP) were quantified by pre-commercial ELISA assays, developed by VitaK (Maastricht, The Netherland) RESULTS: Lp-PLA2 activity was independently positively associated with desphospho-uncarboxylated MGP (dp-ucMGP) [β coeff = 0.098, p=0.006]. 1SD of Lp-PLA2 activity was associated with 37% increased risk (p=0.001) of elevated dp-ucMGP (≥977 pmol/L, top quartile). In the Cox proportional hazard model adjusted for conventional risk factors, the patients in the highest quartile of dp-ucMGP or lowest quintile of total-uncarboxylated ucMGP (<2660 nmol/L) had higher risk of all-cause mortality [HRR 2.79 (95% CI 1.97-3.94) and HRR 1.69 (95% CI 1.18-2.42), respectively]. We observed no effect of high Lp-PLA2 activity (≥195 nmol/min/mL) on total mortality. CONCLUSIONS: We assume that Lp-PLA2 is involved in vascular calcification and that dp-ucMGP is a more appropriate biomarker of residual risk than Lp-PLA2 itself.
- 650 _2
- $a 1-alkyl-2-acetylglycerofosfocholinesterasa $x krev $7 D043203
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a biologické markery $x krev $7 D015415
- 650 _2
- $a proteiny vázající vápník $x krev $7 D002135
- 650 _2
- $a kardiovaskulární nemoci $x krev $x mortalita $7 D002318
- 650 _2
- $a extracelulární matrix - proteiny $x krev $7 D016326
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a proporcionální rizikové modely $7 D016016
- 650 _2
- $a prospektivní studie $7 D011446
- 650 _2
- $a rizikové faktory $7 D012307
- 650 _2
- $a analýza přežití $7 D016019
- 651 _2
- $a Nizozemsko $7 D009426
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Mlíková Seidlerová, Jitka, $u 2nd Department of Internal Medicine, Medical Faculty of Charles University and University Hospital, Pilsen, Czech Republic; Biomedical Center, Medical Faculty of Charles University, Pilsen, Czech Republic. $d 1977- $7 xx0096735
- 700 1_
- $a Vaněk, Jiří $u 2nd Department of Internal Medicine, Medical Faculty of Charles University and University Hospital, Pilsen, Czech Republic. $7 xx0273624
- 700 1_
- $a Kielbergerová, Lenka $u Department of Neurology, University Hospital, Pilsen, Czech Republic. $7 xx0273846
- 700 1_
- $a Bruthans, Jan, $u 2nd Department of Internal Medicine, Medical Faculty of Charles University and University Hospital, Pilsen, Czech Republic; Centre for Cardiovascular Prevention of the First Faculty of Medicine, Charles University and Thomayer Hospital, Prague, Czech Republic. $d 1948- $7 jn20000810219
- 700 1_
- $a Filipovský, Jan, $u 2nd Department of Internal Medicine, Medical Faculty of Charles University and University Hospital, Pilsen, Czech Republic; Biomedical Center, Medical Faculty of Charles University, Pilsen, Czech Republic. $d 1958- $7 xx0058293
- 700 1_
- $a Wohlfahrt, Peter $u Centre for Cardiovascular Prevention of the First Faculty of Medicine, Charles University and Thomayer Hospital, Prague, Czech Republic; International Clinical Research Centre, St. Anne's University Hospital Brno, Brno, Czech Republic. $7 xx0230851
- 700 1_
- $a Cífková, Renata, $u Centre for Cardiovascular Prevention of the First Faculty of Medicine, Charles University and Thomayer Hospital, Prague, Czech Republic; International Clinical Research Centre, St. Anne's University Hospital Brno, Brno, Czech Republic. $d 1955- $7 nlk20010094490
- 700 1_
- $a Trefil, Ladislav $u Department of Clinical Biochemistry and Hematology, University Hospital Pilsen, Pilsen, Czech Republic. $7 xx0099653
- 700 1_
- $a Knapen, Marjo H J $u VitaK & Cardiovascular Research Institute Maastricht, Maastricht University, Maastricht, The Netherlands.
- 700 1_
- $a Drummen, Nadja E A $u VitaK & Cardiovascular Research Institute Maastricht, Maastricht University, Maastricht, The Netherlands.
- 700 1_
- $a Vermeer, Cees $u VitaK & Cardiovascular Research Institute Maastricht, Maastricht University, Maastricht, The Netherlands.
- 773 0_
- $w MED00003202 $t Maturitas $x 1873-4111 $g Roč. 80, č. 1 (2015), s. 82-88
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/25458708 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20160722 $b ABA008
- 991 __
- $a 20170523161717 $b ABA008
- 999 __
- $a ok $b bmc $g 1155697 $s 945555
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2015 $b 80 $c 1 $d 82-88 $e 20141016 $i 1873-4111 $m Maturitas $n Maturitas $x MED00003202
- GRA __
- $a NT12102 $p MZ0
- GRA __
- $a NT13186 $p MZ0
- LZP __
- $a Pubmed-20160722
